Cambridge Centre for Brain Repair and MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Cambridge Eye Unit, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK.
Eye (Lond). 2022 Apr;36(4):818-826. doi: 10.1038/s41433-021-01535-9. Epub 2021 Apr 28.
BACKGROUND/OBJECTIVES: REALITY is an international observational retrospective registry of LHON patients evaluating the visual course and outcome in Leber hereditary optic neuropathy (LHON).
SUBJECTS/METHODS: Demographics and visual function data were collected from medical charts of LHON patients with visual loss. The study was conducted in 11 study centres in the United States of America and Europe. The collection period extended from the presymptomatic stage to at least more than one year after onset of vision loss (chronic stage). A Locally Weighted Scatterplot Smoothing (LOWESS) local regression model was used to analyse the evolution of best-corrected visual acuity (BCVA) over time.
44 LHON patients were included; 27 (61%) carried the m.11778G>A ND4 mutation, 8 (18%) carried the m.3460G>A ND1 mutation, and 9 (20%) carried the m.14484T>C ND6 mutation. Fourteen (32%) patients were under 18 years old at onset of vision loss and 5 (11%) were below the age of 12. The average duration of follow-up was 32.5 months after onset of symptoms. At the last observed measure, mean BCVA was 1.46 LogMAR in ND4 patients, 1.52 LogMAR in ND1 patients, and 0.97 LogMAR in ND6 patients. The worst visual outcomes were reported in ND4 patients aged at least 15 years old at onset, with a mean BCVA of 1.55 LogMAR and no tendency for spontaneous recovery. The LOESS modelling curve depicted a severe and permanent deterioration of BCVA.
Amongst LHON patients with the three primary mtDNA mutations, adult patients with the m.11778G>A ND4 mutation had the worst visual outcomes, consistent with prior reports.
背景/目的:REALITY 是一项国际性的 LHON 患者观察性回顾性登记研究,旨在评估 Leber 遗传性视神经病变 (LHON) 的视觉过程和结局。
受试者/方法:从视觉丧失的 LHON 患者的病历中收集人口统计学和视觉功能数据。该研究在美国和欧洲的 11 个研究中心进行。收集期从亚临床阶段延伸到视力丧失后至少一年(慢性阶段)。使用局部加权散点平滑 (LOWESS) 局部回归模型分析最佳矫正视力 (BCVA) 随时间的演变。
共纳入 44 例 LHON 患者;27 例(61%)携带 m.11778G>A ND4 突变,8 例(18%)携带 m.3460G>A ND1 突变,9 例(20%)携带 m.14484T>C ND6 突变。14 例(32%)患者在视力丧失时年龄小于 18 岁,5 例(11%)年龄小于 12 岁。症状发作后平均随访时间为 32.5 个月。最后一次观察时,ND4 患者的平均 BCVA 为 1.46 LogMAR,ND1 患者为 1.52 LogMAR,ND6 患者为 0.97 LogMAR。在发病时年龄至少 15 岁的 ND4 患者中报告了最差的视力结果,平均 BCVA 为 1.55 LogMAR,无自发恢复趋势。LOESS 模型曲线描绘了 BCVA 的严重和永久性恶化。
在携带三种主要 mtDNA 突变的 LHON 患者中,携带 m.11778G>A ND4 突变的成年患者视力结果最差,与既往报道一致。